Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced its participation in the World Lung Cancer Conference scheduled for September 6-9, 2025, in Barcelona, Spain. Principal Investigator Dr. Karen Reckamp will present initial Phase 1 data for ENV105 in non-small cell lung cancer patients during the conference.

The presentation, titled "Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Patients," focuses on the combination therapy of ENV105 with osimertinib. The open-label trial's primary objective is to evaluate the safety and tolerability of this treatment approach. This research represents a significant step forward in addressing treatment resistance in lung cancer patients.

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. The elevation of CD105 in response to standard therapy often results in resistance and disease relapse. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. The company maintains its newsroom at https://ibn.fm/KAPA where investors can access the latest updates.

Currently, ENV105 is advancing through multiple clinical trials, including a Phase 2 clinical trial for castrate-resistant prostate cancer and the Phase 1 trial for lung cancer that will be discussed at the conference. These trials aim to address significant unmet medical needs in oncology, particularly focusing on patients who have developed resistance to existing treatments.

The World Lung Cancer Conference presentation provides an important platform for sharing early clinical data with the global oncology community. The findings could have substantial implications for lung cancer treatment protocols worldwide, potentially offering new hope for patients with advanced, EGFR-mutated non-small cell lung cancer who face limited treatment options due to drug resistance.

For those interested in the full details of the announcement, the complete press release is available at https://ibn.fm/5JjZJ. The conference presentation marks a critical milestone in the development of ENV105 and demonstrates Kairos Pharma's commitment to advancing innovative cancer therapeutics that address the challenging issue of treatment resistance in oncology.